New insider activity at Dexcom ( (DXCM) ) has taken place on August 18, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Mark Foletta recently sold 195 shares of Dexcom stock, amounting to a total value of $15,900. This transaction highlights a notable move in the trading activities of Dexcom’s leadership.
Recent Updates on DXCM stock
Dexcom recently reported its Q2 2025 earnings, highlighting significant revenue growth of 15% year-over-year, reaching $1.16 billion. This growth was driven by expanded coverage for type 2 non-insulin users and international successes, including new coverage in Ontario, Canada. The company also received FDA clearance for its 15-day G7 System, expected to enhance its market position. Despite these advancements, Dexcom faced challenges with declining gross margins due to investments in supply chain stabilization and a receiver recall. Analysts have raised price targets for Dexcom, citing its robust revenue growth, strategic product launches, and optimistic future guidance, which anticipates continued expansion and a strong cash position to capitalize on strategic opportunities.
Spark’s Take on DXCM Stock
According to Spark, TipRanks’ AI Analyst, DXCM is a Outperform.
Dexcom’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. However, the high P/E ratio and mixed technical indicators present some risks. The company’s strategic initiatives and growth prospects in the medical devices industry support a positive outlook, but valuation concerns limit the overall score.
To see Spark’s full report on DXCM stock, click here.
More about Dexcom
YTD Price Performance: 3.12%
Average Trading Volume: 3,403,563
Technical Sentiment Signal: Sell
Current Market Cap: $31.74B